CLOs on the Move

Avidon Health

www.avidonhealth.com

 
Launched in 2020 following MedPro Wellness acquisition of SelfHelpWorks, Avidon Health is a team of behavior change experts who are passionate about providing health strategies that empower people to make positive life changes. We focus on the individual rather than the condition using innovative engagement technology, impactful courses and content, and care team support to drive meaningful outcomes at scale. Our mission: to change lives by fixing the engagement problem in healthcare.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Upper Chesapeake Health

Established as a non-profit organization in 1995, the Upper Chesapeake Health Foundation is dedicated to supporting UCH and its vision to create the healthiest community in Maryland. The funds raised are managed in accordance with donor wishes,

Colusa Regional Medical Center

Colusa Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Colusa Regional Medical Center is based in Colusa, CA. You can find more information on Colusa Regional Medical Center at www.colusamedicalcenter.org

InfoQuest Clinical Network Inc

InfoQuest Clinical Network Inc is a Alvarado, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Creating Wellness

Creating Wellness is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.